Combination chemotherapy, Adriamycin, bleomycin, vincristine (ABV) with dideoxyinosine (ddI) or dideoxycytidine (ddC) in advanced AIDS-related Kaposi's sarcoma (ACTG 163) (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Combination chemotherapy, Adriamycin, bleomycin, vincristine (ABV) with dideoxyinosine (ddI) or dideoxycytidine (ddC) in advanced AIDS-related Kaposi's sarcoma (ACTG 163) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 14:A822 1995. Unique Identifier : AIDSLINE ICDB/95613974
Mitsuyasu R; Gill P; Paredes J; Ratner L; Remick S; Testa M; et al; UCLA, Los Angeles, CA

Abstract: Objectives: to determine the toxicity and response to therapy of cytotoxic chemotherapy (ABV) with either ddI or ddC in patients with advanced Kaposi's sarcoma (KS). Methods: patients with HIV infection and multiple mucocutaneous (ie, greater than or equal to 25) lesions and/or visceral KS and who had not received prior chemotherapy were randomized to receive either ddI (200 mg bid if greater than or equal to 60 kg or 125 mg bid if less than 60 kg) or ddC (0.75 mg tid if greater than or equal to 50 kg or 0.375 mg tid if less than 50 kg) and were treated with q 2 weekly IV chemotherapy (A 20 mg/m2, B 10 u/m2, V 1 mg). Toxicity assessment were done q 2 weeks and tumor response by ACTG criteria were done q 4 weeks. Results: A total of 81 patients were enrolled and 74 were evaluable (36 ddI and 38 ddC). The 2 groups had similar baseline characteristics. At the time of analysis, 71 patients had come off treatment and 10 are still receiving treatment with a median follow-up of 9 mo (1-36). Toxicities have been minimal and primarily attributable to chemotherapy (eg, neutropenia in 37%, nausea, and LFT elevation). Peripheral neuropathy occurred in 9 patients (6 ddI, 3 ddC), all less than or equal to grade 2 and was not dose limiting. The overall partial response rates were 58% in the ddI treated group and 60% in the ddC treated patients with median duration of response 20 wk with ddI and 19 wk with ddC. There were no CRs. Conclusion: ABV can be administered concurrently with ddI or ddC with minimal toxicity. Peripheral neuropathy occurs infrequently with these regimens. Tumor responses and response duration are good, and this regimen can be recommended for treatment of advanced stage patients with Kaposi's sarcoma.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS/*DRUG THERAPY Antineoplastic Agents, Combined/*THERAPEUTIC USE Bleomycin/ADMINISTRATION & DOSAGE Comparative Study Didanosine/*THERAPEUTIC USE Doxorubicin/ADMINISTRATION & DOSAGE Follow-Up Studies Human HIV Infections/COMPLICATIONS/DRUG THERAPY Sarcoma, Kaposi's/*DRUG THERAPY/ETIOLOGY/PATHOLOGY Time Factors Vinblastine/ADMINISTRATION & DOSAGE Zalcitabine/*THERAPEUTIC USE ABSTRACT CLINICAL TRIAL RANDOMIZED CONTROLLED TRIAL
951230
M95C3211

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .